Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ISDE guidelines on the management of cT2N0 esophageal cancer.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026

Same author

Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R.

Cancer treatment and research communications·2025

Same author

A gut microbial signature for combination immune checkpoint blockade across cancer types.

Nature medicine·2024

Same author

A tailored approach to horizon scanning for cancer medicines.

Journal of cancer policy·2023

Same author

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.

British journal of cancer·2023

Search research articles

Related Experiment Video

Updated: Jan 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Monoclonal antibodies in solid tumours.

Ben Markman¹, Josep Tabernero

¹Medical Oncology Service, Vall d'Hebron University Hospital, P. Vall d'Hebron, Barcelona, Spain.

Current Clinical Pharmacology

|April 22, 2010

Summary

This summary is machine-generated.

Monoclonal antibodies (mAbs) are vital for treating solid tumors by targeting cancer pathways. Continued research is needed for improved design, patient selection, and personalized cancer therapies.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Jan 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Area of Science:

Oncology
Immunotherapy
Drug Development

Background:

Monoclonal antibodies (mAbs) are key therapeutics for solid tumors.
They target specific cell surface receptors or extracellular ligands involved in cancer progression.
Approved mAbs include trastuzumab, cetuximab, panitumumab, bevacizumab, and catumaxomab for various cancers.

Purpose of the Study:

To review current monoclonal antibody therapies for solid tumors.
To discuss challenges and future directions in mAb development and application.
To highlight the need for enhanced strategies in drug design and patient stratification.

Main Methods:

Review of currently approved monoclonal antibodies for solid tumor treatment.
Analysis of their mechanisms of action and clinical applications.
Discussion of research and development efforts in the field.

Main Results:

Several mAbs are approved and used for breast, colorectal, and lung cancers.
Despite successes, challenges and disappointments persist in mAb therapy.
Ongoing research focuses on improving efficacy and patient outcomes.

Conclusions:

Monoclonal antibodies represent a significant advancement in solid tumor treatment.
Future efforts must focus on intelligent compound design, biomarker discovery, and personalized medicine.
Enhanced strategies are crucial for maximizing the therapeutic potential of mAbs.